Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Praxis Precision Medicines, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001689548-26-000083
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Elsunersen | 8,141 | 1,317 | 11,338 | 2,078 |
| Other early stage assets | 5,471 | 1,417 | 8,713 | 2,522 |
| Personnel-related expenses | 18,943 | 11,913 | 36,673 | 24,943 |
| Stock-based compensation expense | 11,309 | 7,770 | 28,421 | 16,556 |
| Depreciation expense | 33 | 46 | 72 | 93 |
| Other segment expenses(a) | 12,851 | 6,753 | 24,940 | 15,129 |
| Other income, net | 13,184 | 4,940 | 26,483 | 10,372 |
| Consolidated net loss | $(83,720) | $(71,127) | $(176,281) | $(140,423) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Praxis Precision Medicines, Inc.'s D&A?
- Praxis Precision Medicines, Inc. (PRAX) reported D&A of $33K in Q2 2026.
- How has Praxis Precision Medicines, Inc.'s D&A changed year-over-year?
- Praxis Precision Medicines, Inc.'s D&A decreased by 28.3% year-over-year, from $46K to $33K.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s D&A?
- Over 4 years (2021 to 2025), Praxis Precision Medicines, Inc.'s D&A has grown at a -6.3% compound annual growth rate (CAGR), from $182K to $140K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Praxis Precision Medicines, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude